Clinical Trial Update: LCZ696 in Advanced LV Hypertrophy and HFpEF [Phase 2]

View source ↗

Summary

A Phase 2 trial of LCZ696 (sacubitril/valsartan) in advanced left ventricular hypertrophy and heart failure with preserved ejection fraction has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Preserved Ejection Fraction
• Hypertension

Drugs mentioned

• LCZ696 (sacubitril/valsartan)

Snippet

Sponsor: National Medical Research Center for Cardiology, Ministry of Health of Russian Federation | Conditions: Heart Failure, Essential Hypertension | Phase 2 | Status: COMPLETED